Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress™ 2021 (EASL)

SAN MATEO, Calif., April 23, 2021 /PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that additional clinical and biomarker research on its lead product candidate, currently being evaluated as a potential treatment for nonalcoholic steatohepatitis (NASH), will be shared via a poster presentation at The International Liver Congress™ 2021 (EASL), which will be held virtually from June 23-26, 2021.

Marie O'Farrell, PhD, will present results from an ongoing Phase 2 clinical trial of TVB-2640 in NASH patients in the poster entitled "Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 Study of FASN Inhibitor TVB-2640."

Details of the presentation are as follows: 

TVB-2640 is a wholly-owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs. FASN is also the only enzyme in the human body capable of converting metabolized sugars into palmitate.  In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three major drivers of the disease: excess accumulation of liver fat, inflammation and fibrosis.

About Sagimet
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally-discovered, selective FASN inhibitors for the treatment of several therapeutic areas of high unmet medical need including liver disease and specific cancers targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors. www.sagimet.com.

SOURCE Sagimet Biosciences

Related Links

http://www.sagimet.com